CXCR4 blockade improves leukemia eradication by allogeneic lymphocyte infusion

American Journal of Hematology, EarlyView.
Source: American Journal of Hematology - Category: Hematology Authors: Source Type: research

Related Links:

Conditions:   Blasts Under 5 Percent of Peripheral Blood White Cells;   Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level;   IDH2 Gene Mutation;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia Interventions:   Drug: Enasidenib;   Procedure: Hematopoietic Cell Transplantation Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Lymphocytic Leukemia Intervention:   Sponsor:   Brno University Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This article provides information on the current state of the science related to commercially available CAR T-cell products and examines how CAR T-cell science is evolving. METHODS: An overview of pathophysiology, indications, and nursing implications of the currently approved CAR T-cell agents is presented. Future directions for CAR T-cell development and treatment indications are discussed. FINDINGS: Tisagenlecleucel (Kymriah®) and axicabtagene ciloleucel (Yescarta®) received approval in 2017 for the treatment of B-cell precursor acute lymphoblastic leukemia in pediatric and young adult patients, and re...
Source: Clinical Journal of Oncology Nursing - Category: Nursing Authors: Tags: Clin J Oncol Nurs Source Type: research
This article presents an overview of pediatric relapsed and refractory acute lymphoblastic leukemia (ALL) and chimeric antigen receptor (CAR) T-cell therapy in pediatric patients. OBJECTIVES: Acute and chronic post-CAR T-cell effects and considerations are discussed, along with survivorship considerations. METHODS: A case study illustrates the identification and management of physiologic and psychosocial sequelae. FINDINGS: B-cell aplasia, hypogammaglobulinemia, infections, and cumulative effects of CAR T-cell therapy and other treatments are a concern in the pediatric population. Unique to pediatric and you...
Source: Clinical Journal of Oncology Nursing - Category: Nursing Authors: Tags: Clin J Oncol Nurs Source Type: research
Abstract BACKGROUND: Many factors can interfere with a patient's ability to cope with a new cancer diagnosis. The method of education delivery may improve satisfaction with teaching and reduce anxiety. Structured DVD education combined with other teaching methods has shown positive results. However, few such studies have included family members. OBJECTIVES: The purpose of this study was to evaluate the impact of structured DVD education versus standard one-on-one education on satisfaction with teaching and on anxiety among patients newly diagnosed with leukemia and lymphoma and their families. METHODS: A...
Source: Clinical Journal of Oncology Nursing - Category: Nursing Authors: Tags: Clin J Oncol Nurs Source Type: research
Publication date: Available online 23 January 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Krzysztof Mądry, Karol Lis, Przemysław Biecek, Magda Młynarczyk, Jagoda Rytel, Michał Górka, Piotr Kacprzyk, Magdalena Dutka, Marek Rodzaj, Łukasz Bołkun, Dorota Krochmalczyk, Ewa Łątka, Joanna Drozd-Sokołowska, Anna Waszczuk-Gajda, Wanda Knopińska-Posłuszny, Anna Kopińska, Edyta Subocz, Anna Masternak, Renata Guzicka-Kazimierczak, Lidia GilAbstractBackgroundMyelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML) patients, including those treated wit...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Authors: Yuan T, Zhang F, Zhou X, Li Y, Zhang Y, Xu Y, Wang X Abstract Proteasome inhibitors represent a novel class of drugs that have clinical efficacy against hematological and solid cancer types, including acute myeloid leukaemia, myelodysplastic syndrome an non-small cell lung cancer. It has been demonstrated that the anti-apoptotic protein B-cell lymphoma-2-associated athanogene 3 (BAG3) is induced by proteasome inhibitors in various cancer cells and serves an important role in chemotherapy resistance. The phosphatidylinositol 3-kinase (PI3K)/RAC-α serine/threonine-protein kinase (AKT) pathway is consti...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
AbstractThe antigen-mediated triggering of B cell receptor (BCR) activates the transcription factor NF- κB that regulates the expression of genes involved in B cell differentiation, proliferation, and survival. The tyrosine kinase Btk is essentially required for the activation of NF-κB in BCR signaling through the canonical pathway of IKK-dependent phosphorylation and proteasomal degradation of IκB -α, the main repressor of NF-κB. Here, we provide the evidence of an additional mechanism of NF-κB activation in BCR signaling that is Btk-dependent and IKK-independent. In DeFew B lymphoma ce...
Source: Journal of Molecular Medicine - Category: Molecular Biology Source Type: research
AbstractBackgroundWith the improvement in the survival of breast cancer, developing second primary malignancy becomes a serious health issue. The aim of this study was to explore the survival of breast cancer patients with second primary malignancy, and to evaluate the impact of chemotherapy on the risk of different cancer sites.MethodObtaining data from the Surveillance, Epidemiology, and End Results database, we calculated the standardized incidence ratio (SIR) for second primary malignancy in breast cancer survivors between 2000 and 2014. Overall survival and cancer-specific survival were analyzed with Kaplan –Mei...
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
AbstractThe National Institute for Health and Care Excellence (NICE) invited Pfizer, the manufacturer of inotuzumab ozogamicin (henceforth inotuzumab), to submit clinical- and cost-effectiveness evidence for inotuzumab as part of NICE ’s single technology appraisal process. The Centre for Reviews and Dissemination and the Centre for Health Economics, both at the University of York, were commissioned as the independent evidence review group (ERG). The clinical-effectiveness data were from a multicentre randomised controlled tria l that compared inotuzumab with standard of care (SoC), where SoC was the investigator&rsq...
Source: PharmacoEconomics - Category: Health Management Source Type: research
More News: Hematology | Leukemia